Leveraging Salmonella typhi Ty21a to activate innate and adaptive immune responses against cancer cells
Socium Therapeutics is developing an orally administered immunotherapy platform based on recombinant Salmonella typhi Ty21a, the same strain that has been used as the typhoid vaccine since 1989. Socium’s platform – CReST (Cross-presenting Recombinant Salmonella typhi Ty21a) – induces an innate immune response from Salmonella pathogenesis and an adaptive immune response by cross-presenting tumor-specific antigen to enhance activation of killer T-cells.

News

Latest News

Joachim Fensterle, PhD joins Advisory Board of Socium Therapeutics

Joachim Fensterle, PhD joins Advisory Board of Socium Therapeutics

July 2, 2018 -- Today, Socium Therapeutics announced that Joachim Fensterle, PhD has joined the company's Scientific Advisory Board. After receiving his PhD in immunology / infection biology from the Max Planck Institute for Infection Biology, Dr. Fensterle moved to...

Contact

Get InTouch

Email:

info@sociumtherapeutics.com

Phone:

(973) 585-6202

Address:

90 E. Halsey Road
Suite 311
Parsippany, NJ 07054